NUVL insider buying and SEC filings, explained
Nuvalent, Inc. · CIK 1861560
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$70.9M
Planned sales (10b5-1)
$53.6M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Jul 9, 2026 | Planned (10b5-1) | Henry E. Pelish (Chief Scientific Officer) sold 2,111 shares at $123.81 ($261K), marked as a 10b5-1 plan trade. Holdings down 3% to 63,493 shares. | SEC filing Filed Jul 10, 2026 |
| Jul 6, 2026 | Planned (10b5-1) | James Richard Porter (CEO and Director) sold 30,000 shares at about $123.72 ($3.7M), marked as a 10b5-1 plan trade. Holdings down 8% to 324,879 shares. | SEC filing Filed Jul 8, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Darlene Noci (Chief Development Officer) sold 23,000 shares at about $123.59 ($2.8M), marked as a 10b5-1 plan trade. Holdings down 28% to 58,117 shares. | SEC filing Filed Jul 6, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Alexandra Balcom (CFO) sold 11,430 shares at about $123.58 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 12% to 85,533 shares. | SEC filing Filed Jul 6, 2026 |
| Jun 29, 2026 | Planned (10b5-1) | Darlene Noci (Chief Development Officer) sold 5,500 shares at about $123.51 ($679K), marked as a 10b5-1 plan trade. Holdings down 9% to 58,117 shares. | SEC filing Filed Jul 1, 2026 |
| Jun 9, 2026 | Planned (10b5-1) | Darlene Noci (Chief Development Officer) sold 20,000 shares at $122.81 ($2.5M), marked as a 10b5-1 plan trade. Holdings down 26% to 58,117 shares. | SEC filing Filed Jun 11, 2026 |
| Jun 8, 2026 | Planned (10b5-1) | James Richard Porter (CEO and Director) sold 30,000 shares at about $88.53 ($2.7M), marked as a 10b5-1 plan trade. Holdings down 8% to 324,879 shares. | SEC filing Filed Jun 10, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Alexandra Balcom (CFO) sold 11,430 shares at about $98.69 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 12% to 85,533 shares. | SEC filing Filed Jun 3, 2026 |
| May 28, 2026 | Planned (10b5-1) | Deborah Ann Miller (Chief Legal Officer) sold 5,500 shares at about $107.84 ($593K), marked as a 10b5-1 plan trade. Holdings down 8% to 59,634 shares. | SEC filing Filed Jun 1, 2026 |
| May 28, 2026 | Planned (10b5-1) | Darlene Noci (Chief Development Officer) sold 5,500 shares at about $107.80 ($593K), marked as a 10b5-1 plan trade. Holdings down 9% to 58,117 shares. | SEC filing Filed Jun 1, 2026 |
| May 4, 2026 | Planned (10b5-1) | James Richard Porter (CEO and Director) sold 30,000 shares at about $101.69 ($3.1M), marked as a 10b5-1 plan trade. Holdings down 8% to 324,879 shares. | SEC filing Filed May 6, 2026 |
| May 1, 2026 | Planned (10b5-1) | Alexandra Balcom (CFO) sold 11,430 shares at about $99.00 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 12% to 85,533 shares. | SEC filing Filed May 5, 2026 |
| Apr 30, 2026 | Planned (10b5-1) | Deborah Ann Miller (Chief Legal Officer) sold 5,500 shares at about $99.22 ($546K), marked as a 10b5-1 plan trade. Holdings down 8% to 59,634 shares. | SEC filing Filed May 1, 2026 |
| Apr 29, 2026 | Planned (10b5-1) | Darlene Noci (Chief Development Officer) sold 5,500 shares at about $99.55 ($548K), marked as a 10b5-1 plan trade. Holdings down 9% to 58,117 shares. | SEC filing Filed May 1, 2026 |
| Apr 9, 2026 | Planned (10b5-1) | Henry E. Pelish (Chief Scientific Officer) sold 3,093 shares at about $104.48 ($323K), marked as a 10b5-1 plan trade. Holdings down 5% to 65,604 shares. | SEC filing Filed Apr 13, 2026 |
| Apr 6, 2026 | Planned (10b5-1) | James Richard Porter (CEO and Director) sold 30,000 shares at about $103.77 ($3.1M), marked as a 10b5-1 plan trade. Holdings down 8% to 324,879 shares. | SEC filing Filed Apr 8, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Alexandra Balcom (CFO) sold 11,430 shares at about $105.21 ($1.2M), marked as a 10b5-1 plan trade. Holdings down 12% to 85,533 shares. | SEC filing Filed Apr 3, 2026 |
| Mar 30, 2026 | Planned (10b5-1) | Darlene Noci (Chief Development Officer) sold 5,500 shares at about $97.81 ($538K), marked as a 10b5-1 plan trade. Holdings down 9% to 58,117 shares. | SEC filing Filed Apr 1, 2026 |
| Mar 26, 2026 | Planned (10b5-1) | Deborah Ann Miller (Chief Legal Officer) sold 5,500 shares at about $98.73 ($543K), marked as a 10b5-1 plan trade. Holdings down 8% to 59,634 shares. | SEC filing Filed Mar 30, 2026 |
| Mar 24–25, 2026 | Planned (10b5-1) | Alexandra Balcom (CFO) sold 25,130 shares between Mar 24 and Mar 25 at about $98.15 ($2.5M), marked as a 10b5-1 plan trade. Holdings down 23% to 85,533 shares. | SEC filing Filed Mar 26, 2026 |
| Mar 12–13, 2026 | Planned (10b5-1) | Henry E. Pelish (Chief Scientific Officer) sold 35,104 shares between Mar 12 and Mar 13 at about $98.08 ($3.4M), marked as a 10b5-1 plan trade. Holdings down 35% to 65,604 shares. | SEC filing Filed Mar 16, 2026 |
| Mar 6, 2026 | Planned (10b5-1) | James Richard Porter (CEO and Director) sold 30,000 shares at about $98.99 ($3.0M), marked as a 10b5-1 plan trade. Holdings down 8% to 324,879 shares. | SEC filing Filed Mar 10, 2026 |
| Feb 26, 2026 | Planned (10b5-1) | Darlene Noci (Chief Development Officer) sold 5,500 shares at about $103.03 ($567K), marked as a 10b5-1 plan trade. Holdings down 9% to 58,117 shares. | SEC filing Filed Mar 2, 2026 |
| Feb 26, 2026 | Planned (10b5-1) | Deborah Ann Miller (Chief Legal Officer) sold 5,500 shares at about $103.05 ($567K), marked as a 10b5-1 plan trade. Holdings down 8% to 59,634 shares. | SEC filing Filed Mar 2, 2026 |
| Jan 29, 2026 | Planned (10b5-1) | Darlene Noci (Chief Development Officer) sold 5,500 shares at about $102.08 ($561K), marked as a 10b5-1 plan trade. Holdings down 9% to 58,117 shares. | SEC filing Filed Feb 2, 2026 |
| Jan 21–22, 2026 | Planned (10b5-1) | Deborah Ann Miller (Chief Legal Officer) sold 15,000 shares between Jan 21 and Jan 22 at about $110.15 ($1.7M), marked as a 10b5-1 plan trade. Holdings down 20% to 59,634 shares. | SEC filing Filed Jan 23, 2026 |
| Jan 5–6, 2026 | Planned (10b5-1) | Henry E. Pelish (Chief Scientific Officer) sold 5,160 shares between Jan 5 and Jan 6 at about $97.24 ($502K), marked as a 10b5-1 plan trade. Holdings down 7% to 65,888 shares. | SEC filing Filed Jan 7, 2026 |
| Jan 5–6, 2026 | Planned (10b5-1) | Darlene Noci (Chief Development Officer) sold 7,417 shares between Jan 5 and Jan 6 at about $97.25 ($721K), marked as a 10b5-1 plan trade. Holdings down 15% to 40,617 shares. | SEC filing Filed Jan 7, 2026 |
| Jan 5–6, 2026 | Planned (10b5-1) | Deborah Ann Miller (Chief Legal Officer) sold 6,952 shares between Jan 5 and Jan 6 at about $97.26 ($676K), marked as a 10b5-1 plan trade. Holdings down 14% to 42,134 shares. | SEC filing Filed Jan 7, 2026 |
| Jan 5–6, 2026 | Planned (10b5-1) | Christopher Durant Turner (Chief Medical Officer) sold 7,417 shares between Jan 5 and Jan 6 at about $97.25 ($721K), marked as a 10b5-1 plan trade. Holdings down 12% to 55,130 shares. | SEC filing Filed Jan 7, 2026 |
| Jan 5–6, 2026 | Planned (10b5-1) | Alexandra Balcom (CFO) sold 7,417 shares between Jan 5 and Jan 6 at about $97.25 ($721K), marked as a 10b5-1 plan trade. Holdings down 8% to 81,733 shares. | SEC filing Filed Jan 7, 2026 |
| Jan 5–6, 2026 | Planned (10b5-1) | James Richard Porter (CEO and Director) sold 27,433 shares between Jan 5 and Jan 6 at about $97.26 ($2.7M), marked as a 10b5-1 plan trade. Holdings down 9% to 278,629 shares. | SEC filing Filed Jan 7, 2026 |
| Jan 2, 2026 | Planned (10b5-1) | Deborah Ann Miller (Chief Legal Officer) sold 10,000 shares at about $100.51 ($1.0M), marked as a 10b5-1 plan trade. Holdings down 17% to 49,086 shares. | SEC filing Filed Jan 5, 2026 |
| Dec 30, 2025 | Planned (10b5-1) | Darlene Noci (Chief Development Officer) sold 4,000 shares at about $100.04 ($400K), marked as a 10b5-1 plan trade. Holdings down 8% to 48,034 shares. | SEC filing Filed Jan 2, 2026 |
| Dec 8, 2025 | Planned (10b5-1) | Alexandra Balcom (CFO) sold 7,084 shares at about $110.32 ($782K), marked as a 10b5-1 plan trade. Holdings down 11% to 54,650 shares. | SEC filing Filed Dec 10, 2025 |
| Nov 28, 2025 | Planned (10b5-1) | Darlene Noci (Chief Development Officer) sold 4,000 shares at about $108.58 ($434K), marked as a 10b5-1 plan trade. Holdings down 8% to 48,034 shares. | SEC filing Filed Dec 2, 2025 |
| Nov 24, 2025 | Planned (10b5-1) | Matthew Shair (Director) sold 7,500 shares directly and indirectly at about $109.37 ($820K), marked as a 10b5-1 plan trade. Direct holdings down <1% to 1,377,194 shares. | SEC filing Filed Nov 26, 2025 |
| Nov 24, 2025 | Sale | James E Flynn (Director and 10% owner) sold 742,574 shares indirectly (by entity) at $95.45 ($70.9M). Holdings by entity down 4% to 8,299,225 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 7 other reporting owners. | SEC filing Filed Nov 24, 2025 |
| Nov 17–18, 2025 | Planned (10b5-1) | Alexandra Balcom (CFO) sold 20,729 shares between Nov 17, 2025 and Nov 18, 2025 at about $99.62 ($2.1M), marked as a 10b5-1 plan trade. Holdings down 25% to 61,734 shares. | SEC filing Filed Nov 19, 2025 |
| Nov 17, 2025 | Planned (10b5-1) | Deborah Ann Miller (Chief Legal Officer) sold 24,200 shares at about $105.50 ($2.6M), marked as a 10b5-1 plan trade. Holdings down 33% to 49,086 shares. | SEC filing Filed Nov 19, 2025 |
64 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow NUVL in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.